<DOC>
	<DOCNO>NCT00086567</DOCNO>
	<brief_summary>This study develop blood test use predict relapse ovarian , peritoneal , fallopian tube cancer . The type test call proteomics , study protein live cell . The test identify certain protein might represent pattern , `` fingerprint , '' indicate increase risk disease relapse . Women Stage III IV epithelial ovarian cancer , primary peritoneal cancer , fallopian tube cancer remission may eligible study . Candidates screen medical history physical examination , blood test , review pathology report surgery , compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan abdomen pelvis ( chest cancer spread chest ) . Participants clinic visit every 3 month physical examination ( include pelvic examination ) , blood draw routine research test , review feeling . Every 6 month CT scan abdomen , pelvis , possibly chest . When patient remission 4 year , blood draw do every 6 month CT scan do yearly . Patients whose cancer return ( base CA-125 blood test , CT scan , physical examination ) end participation study . Patients abnormal CT scan physical examination may ask undergo tumor biopsy ( surgical removal piece tumor tissue ) research purpose .</brief_summary>
	<brief_title>Predictors Relapse Ovarian , Peritoneal , Fallopian Tube Cancers</brief_title>
	<detailed_description>Background : Over 80 % patient advanced stage epithelial ovarian cancer relapse Serum biomarkers need predictor persistent disease relapse CA-125 less satisfactory clinical tool detect relapse A serum repository sample woman ovarian cancer need develop validate multiple test create ovarian cancer recurrence screen . Objectives : To create multi-institutional repository investigation serum proteomic signature profile epithelial ovarian cancer relapse develop validate To determine sensitivity specificity proteomic signature profile relapse To compare accuracy proteomic evaluation CA125 classify patient disease progression To identify temporal relationship rise CA125 value versus development proteomic signature profile relapse . To detect impact study participation quality life . To collect epidemiological data patient target population Eligibility : Patients first remission treatment FIGO stage III/IV primary peritoneal , fallopian tube , epithelial ovarian carcinoma define normal CA125 , evidence disease abdominopelvic CT scan , normal post-hysterectomy physical exam . Entry within 12 week last administration chemotherapy . S/P surgical debulking completion primary therapy platinum/taxane-containing chemotherapy total 8 cycle . Laboratory evidence good end organ function . Design : Phase Trial : Biomarker/Laboratory Analysis . Number patient enrol : 400 Planned statistical analysis primary endpoint : Training set include 100 woman , half remission half recurrent disease . Validation set include 200 woman , half remission half recurrent disease .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : 2.1.1 &lt; TAB &gt; All patient first complete response treatment FIGO stage III/IV primary peritoneal , fallopian tube , epithelial ovarian carcinoma define : normal CA125 , normal posthysterectomy physical exam , evidence disease abdominopelvic CT scan ( noninvasive reassessment , e.g . MRI ) . PET scan acceptable confirmation complete response . 2.1.2 &lt; TAB &gt; Pathology primary tumor must confirm register center prior protocol entry . 2.1.3 &lt; TAB &gt; Entry within 9 week completion final cycle chemotherapy ( within 12 week last administration chemotherapy ) . 2.1.4 &lt; TAB &gt; S/P surgical debulking completion primary therapy platinum/taxane contain chemotherapy 8 total cycle . 2.1.5 &lt; TAB &gt; Patients undergo second look laparotomy laparoscopy microscopic residual disease elect treatment eligible enroll . 2.1.6 &lt; TAB &gt; Histology slide adequate confirm pathology stag must submit coordinating center within 3 month enrollment . ( If available , sample frozen primary tumor also forward ) . 2.1.7 &lt; TAB &gt; Patients must able willing provide inform consent participate trial . 2.1.8 &lt; TAB &gt; Patients must laboratory evidence good end organ function criterion Table 1 . The upper limit normal base upon register center 's laboratory normal range . Laboratory base inclusion criterion : Laboratory Test : AST ( SGOT ) ALT ( SGPT ) Required value : le equal 2.5 time institutional upper limit normal creatinine OR Laboratory Test : Creatinine Required value : Less equal 2.0 Laboratory Test : Creatinine clearance Required Value : Greater equal 45 mL/min/1.73 ( 2 ) patient creatinine level institutional normal . EXCLUSION CRITERIA : 2.2.1 &lt; TAB &gt; Patients nonepithelial ovarian cancer , mixed epithelial/nonepithelial ovarian cancer ( i.e. , Mixed Malignant Mullerian Tumors ) , tumor low malignant potential . Patients stage I II epithelial ovarian , fallopian tube , primary peritoneal cancer . 2.2.2 &lt; TAB &gt; Patients may receive chemotherapy ( therapeutic consolidation ) , maintenance , alternative therapy , radiation therapy . No anticancer therapy kind allow patient onstudy . Replacement hormonal therapy allow must clearly indicated case report form submit . Hormonal anticancer therapy tamoxifen raloxifene permit study . 2.2.3 &lt; TAB &gt; Patients life expectancy le 6 month reason . 2.2.4 &lt; TAB &gt; Patients history invasive malignancy within past five year prior enrollment except curatively treat carcinoma situ cervix , ductal lobular carcinoma situ breast , concomitant stage I endometrial cancer , basal squamous cell skin cancer . 2.2.5 &lt; TAB &gt; Complementary alternative agent use discourage study due possibility use agent may alter serum protein pattern . The Institutional Principal Investigator discretion whether complementary alternative agent usage prevent eligibility case case basis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>September 26, 2016</verification_date>
	<keyword>Blood</keyword>
	<keyword>Testing</keyword>
	<keyword>Gynecologic</keyword>
	<keyword>Urine</keyword>
	<keyword>CA125</keyword>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
</DOC>